Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by nobody – 2019-04-05 08:37 (1018 d 10:13 ago) – Posting: # 20124
Views: 2,943

» The fact that it is also a royal waste of money is of course only secondary.

Full-blown development mode. Accept it. Tell the sponsor you can't do the trial, if you are not qualified for PD-endpoint testing.

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
21,829 posts in 4,566 threads, 1,555 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Monday 17:50 CET (Europe/Vienna)

Discovery consists of seeing what everybody has seen
and thinking what nobody has thought.    Albert Szent-Györgyi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5